JAK

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

JAK

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway.Members of the type I and type II cytokine receptor families depend on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways because they lack catalytic kinase activity. The receptors have two intracellular signal-transducing domains because they are paired polypeptides. Each intracellular domain contains a proline-rich region called a box1/box2 region that is close to the cell membrane and where JAKs bind. The two JAKs are brought close enough to phosphorylate one another after the receptor undergoes a conformational change following association with the corresponding cytokine or ligand. By further phosphorylating and activating STAT transcription factors, JAK autophosphorylation causes a conformational change within itself, enabling it to transduce the intracellular signal. When STATs are activated, they separate from their receptor and coalesce into dimers before moving into the cell nucleus, where they control the transcription of particular genes.

JAK related products

Cat No.	Product Name	CAS No.	Product Description
V51531	(2R,5S)-Ritlecitinib	1792180-79-0	(2R,5S)-Ritlecitinib (2R,5S)-PF-06651600) is a potent and specific JAK3 conjugate (IC50=144.8 nM).
V33936	(3S,4R)-Tofacitinib	1092578-48-7	(3S,4R)-Tofacitinib (Tofacitinib Impurity B) is a less active isomer/enantiomer of Tofacitinib (CP-690550;tasocitinib; Xeljanz), which is an inhibitor of JAK3 (Janus-Associated kinase, IC50 = 1 nM) and an FDA approved drug for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis.
V102608	(R)-9b	1655527-68-6	(R)-9b is a potent ACK1 tyrosine kinase inhibitor (IC50=56 nM) with anticancer activity.
V103326	(R)-α7 nAchR-JAK2-STAT3 agonist 1		(R)-α7 nAchR-JAK2-STAT3 agonist 1 is the R-enantiomer of α7 nAchR-JAK2-STAT3 agonist 1.
V122044	(Rac)-TUL01101	2411222-71-2	(Rac)-TUL01101 is a selective JAK kinase inhibitor.
V122186	(S)-Lomedeucitinib	2328068-38-6	(S)-Lomedeucitinib is the S-enantiomer of lomedeucitinib.
V4262	AT-9283 L-lactate	896466-76-5	AT-9283 L-lactate is a novel, potent multikinase inhibitor with potential antineoplastic activity and has the potential for the treatment of multiple myeloma.
V86300	25-Deacetylcucurbitacin A	1135141-77-3
V127204	5TTU		5TTU is a covalent JAK3 inhibitor.
V115239	AC-430	1241914-87-3	AC-430 is a JAK2 inhibitor.
V77246	APTSTAT3-9R		APTSTAT3-9R is a specific STAT3-binding peptide that can inhibit STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation.
V4261	AT-9283 HCl	896466-61-8	AT9283 is a novel, potent multikinase inhibitor with potential antineoplastic activity and has the potential for the treatment of multiple myeloma.
V0318	AT9283	896466-04-9	AT9283 is a novel, potentand selective inhibitor of multikinase including Aurora A/B,JAK2/3,Abl (T315I)andFlt3 etc.
V0334	AZ 960	905586-69-8	AZ 960 (AZ-960) is a novel, potent, selective and ATP competitive JAK2 (janus kinase) inhibitor with potential antitumor activity.
V0316	AZD1480	935666-88-9	AZD1480 (AZD-1480)is a selective, orally bioavailable andATP-competitive inhibitor of JAK2 (Janus-associated kinase)with potential antitumor activity.
V51513	BD-750	892686-59-8	BD750 is a potent immunological dye for JAK3/STAT5 that can inhibit IL-2-induced, JAK3/STAT5-dependent T cell proliferation/growth.
V0319	BMS-911543	1271022-90-2	BMS-911543 (BMS911543) is a potent, selective and orally bioavailable inhibitor of JAK2 (Janus-associated kinase) with potential anticancer activity.
V102487	BPC 157 acetate	1628202-19-6	BPC 157 Acetate is the acetate salt form of BPC 157.
V3802	Brepocitinib (PF-06700841) tosylate	2140301-96-6	Brepocitinib (PF-06700841) tosylate, the tosylate salt ofBrepocitinib,isa conformationally constrained piperazinyl-pyrimidine-based, Type 1 ATP site inhibitor of TYK2 and JAK1 kinases with IC50 values of 23 nM and 17 nM respectively.
V51526	Butyzamide	1110767-45-7	activator of Mpl